We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Synthetic Platelets Could Eventually Be Used For Biomedical Applications

By LabMedica International staff writers
Posted on 07 Jun 2012
Scientists have succeeded in making synthetic platelets, which after optimization and exhaustive testing, could be suitable for a number of biomedical applications

At University of California (UC) Santa Barbara (USA) scientists used a polymeric template––a core upon which layers of proteins and polyelectrolytes were deposited, layered, and crosslinked to create a stable synthetic platelet-shaped particle. More...
The rigid polymeric core was then dissolved to give the particle the desired flexibility. The particle was then coated with proteins found on the surface of activated natural platelets or damaged blood vessels, a procedure performed by the researchers at Scripps Research Institute (Scripps Research Institute (La Jolla, CA, USA). Scientists at Sanford-Burnham Institute (La Jolla, CA, USA) collaborated in the project.

Smaller than red blood cells, platelets are flexible, disk-shaped cells that are 2-4 µm in size. They are the components of blood that allow it to prevent excessive bleeding and to heal wounds. The synthetic platelets can be used not only to perform the typical functions of human platelets. They may also be used to carry imaging agents to identify damaged blood vessels or to deliver drugs that dissolve blood clots.

The synthetic platelets represent one of the most advanced efforts over the last century to mimic platelet function. While clotting factors and platelets from outside donors are used widely to halt bleeding, immune system responses and thrombosis have been issues.

The development is a significant milestone in the field of biomimetic materials," said Samir Mitragotri, professor of chemical engineering, director of UC Santa Barbara's Center for Bioengineering, and an author of a paper published in the journal Advanced Materials on May 29, 2012. "By capitalizing on our capabilities in engineering materials, […] our synthetic platelets combine unique physical and biological attributes that mimic natural platelets."

Related Links:

University of California, Santa Barbara
Scripps Research Institute
Sanford-Burnham Institute




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Urine Analyzer
respons® UDS100
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.